Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FCYZ5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,901
Award facts
- Contract value 100% obligated
- $37,901.28 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,901.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/1.2 ml powder vials. This delivery order, issued on December 4, 2025, with an ultimate completion date of December 26, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award represents a single delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with its underlying PPV-G GEN V prime vendor contract—awarded November 13, 2025, with a $499,999,999 ceiling and completion date of December 31, 2036—authorizing the issuance of firm fixed-price delivery orders for branded and generic prescription drugs, biologics, over-the-counter medications, and medical consumables. The company's product portfolio encompasses specialty pharmaceuticals, oncology treatments, immunosuppressants, vaccines, and emergency medications, positioning it to support the diverse and specialized pharmaceutical requirements of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FCYZ5?
SPE2DR26FCYZ5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 4, 2025.
How much is contract SPE2DR26FCYZ5 worth?
The government has obligated $37,901 on SPE2DR26FCYZ5.
Is contract SPE2DR26FCYZ5 an order under another contract?
Yes. SPE2DR26FCYZ5 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCYZ5 competed?
The extent of competition for SPE2DR26FCYZ5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award